Business Description
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
Business History
Price Overview
Last updated: May 11, 2026 1:49pm (8m ago)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -1.90
Total Equity: $577.31M
Shares: 1,672,056,160
Total Debt: $378.99M
Cash: $797.80M
EBITDA: $11.38M
Total Debt: $378.99M
Cash: $797.80M
Revenue: $812.03M
Revenue: $812.03M
Revenue: $812.03M
Total Equity: $577.31M
Tax Rate: -690.1%
Equity: $577.31M
Total Debt: $378.99M
Cash: $797.80M
Current Liabilities: $127.15M
Long-Term Debt: $378.82M
Total Debt: $378.99M
Total Equity: $577.31M
Shares: 1,672,056,160
Shares: 1,672,056,160
CapEx: -$16.26M
Shares: 1,672,056,160
Stock Price: $16.15
Net Income: -$537.96M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
| Metric | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $294.0M | $258.5M | $306.1M | $412.3M | $812.0M |
| Cost of Revenue | $109.9M | $178.5M | $216.8M | $233.5M | $272.9M |
| Gross Profit | $184.2M | $80.0M | $89.3M | $178.8M | $539.2M |
| Operating Expenses | $45.1M | $395.8M | $408.9M | $435.9M | $494.1M |
| Operating Income | $139.1M | -$315.8M | -$319.6M | -$257.1M | $45.1M |
| Net Income | $27.7M | -$320.8M | -$341.4M | -$281.9M | -$538.0M |
| EBITDA | $254.5M | -$245.9M | -$260.8M | -$183.0M | $11.4M |
| EPS | $1.55 | $-1.57 | $-1.82 | $-2.70 | $-1.90 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $53.5M | $107.2M | $56.4M | $64.0M | $797.8M |
| Total Current Assets | $214.7M | $516.0M | $242.6M | $215.7M | $997.8M |
| Total Assets | $2.6B | $717.4M | $412.9M | $343.7M | $1.1B |
| Current Liabilities | $320.3M | $136.9M | $95.1M | $165.4M | $127.1M |
| Long-Term Debt | $1.6B | $169.6M | $166.1M | $319.2M | $378.8M |
| Total Liabilities | $1.9B | $2.4B | $2.6B | $2.8B | $548.4M |
| Total Equity | $702.2M | -$1.7B | -$2.1B | -$2.5B | $577.3M |
| Retained Earnings | $503.3M | -$1.7B | -$2.1B | -$2.5B | -$2.5B |
Cash Flow (Annual)
| Metric | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $277.0M | -$285.7M | -$276.1M | -$245.2M | $83.2M |
| Capital Expenditure | -$219.5M | -$42.3M | -$22.3M | -$8.4M | -$16.3M |
| Free Cash Flow | $57.6M | -$328.0M | -$298.4M | -$253.6M | $66.9M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$7.9M | $0 | $0 | $0 | $-113,000 |
| Net Change in Cash | -$6.7M | -$558.2M | -$51.1M | $8.0M | $732.0M |
Analyst Estimates (Annual)
| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$1.2B $1.2B – $1.2B
|
$1.4B $1.4B – $1.4B
|
$1.6B $1.6B – $1.7B
|
$1.8B $1.8B – $1.9B
|
| EBITDA |
-$332.8M -$335.6M – -$330.0M
|
-$389.6M -$390.3M – -$389.0M
|
-$446.3M -$451.6M – -$439.0M
|
-$504.5M -$510.4M – -$496.2M
|
| Net Income |
$641.9M $379.7M – $904.1M
|
$1.1B $677.5M – $1.5B
|
$1.5B $1.5B – $1.6B
|
$2.0B $1.9B – $2.0B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -12.1% | +18.4% | +34.7% | +97.0% |
| Gross Profit Growth | -56.5% | +11.6% | +100.2% | +201.6% |
| Operating Income Growth | -327.0% | -1.2% | +19.5% | +117.5% |
| Net Income Growth | -1,256.8% | -6.4% | +17.4% | -90.8% |
| EBITDA Growth | -196.6% | -6.1% | +29.9% | +106.2% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-03-06 | Power Luke Thomas | A-Award | 63,971.00 | $0.00 | $0 |
| 2026-03-06 | Denton John Russel | A-Award | 63,971.00 | $0.00 | $0 |
| 2026-03-06 | Spetzler David Baxley | A-Award | 83,162.00 | $0.00 | $0 |
| 2026-03-06 | Brille Brian J | A-Award | 83,162.00 | $0.00 | $0 |
| 2026-03-06 | HALBERT DAVID D | A-Award | 320,112.00 | $0.00 | $0 |
| 2026-02-26 | Minor Lloyd | A-Award | 2,492.00 | $20.06 | $49,990 |
| 2026-02-26 | Vacirca Jeff L | A-Award | 2,492.00 | $20.06 | $49,990 |
| 2026-02-26 | Fredrickson David Paul | A-Award | 2,492.00 | $20.06 | $49,990 |
| 2026-02-26 | HALBERT JON | A-Award | 2,492.00 | $20.06 | $49,990 |
| 2026-02-26 | PHILLIPS T DANNY | A-Award | 3,739.00 | $20.06 | $75,004 |
| 2026-02-26 | CASTLEMAN PETER M | A-Award | 5,509.00 | $20.06 | $110,511 |
| 2026-01-09 | CASTLEMAN PETER M | M-Exempt | 2,500.00 | $18.60 | $46,500 |
| 2026-01-09 | CASTLEMAN PETER M | M-Exempt | 2,500.00 | $18.60 | $46,500 |
| 2025-12-11 | Power Luke Thomas | M-Exempt | 37,500.00 | $2.44 | $91,500 |
| 2025-12-11 | Power Luke Thomas | M-Exempt | 24,750.00 | $2.44 | $60,390 |
| 2025-12-11 | Power Luke Thomas | S-Sale | 60,850.00 | $26.56 | $1.6M |
| 2025-12-11 | Power Luke Thomas | S-Sale | 1,400.00 | $27.16 | $38,018 |
| 2025-12-11 | Power Luke Thomas | M-Exempt | 37,500.00 | $2.44 | $91,500 |
| 2025-12-10 | Brille Brian J | G-Gift | 650.00 | $0.00 | $0 |
| 2025-12-11 | Brille Brian J | G-Gift | 650.00 | $0.00 | $0 |